The foundation of TRT’s Mesenchymal Stromal/Stem Cell (MSC) platform technologies is the extensive intellectual property we have developed for the production of the TXP family of therapeutic products. The TXP product family is based on the extraction and isolation of MSCs from a completely non-controversial source of neo-natal human tissue – the umbilical cord. The extracted cells are known as Human Umbilical Cord PeriVascular Cells (HUCPVC). This platform represents the world’s richest source of MSCs that can be engineered (eTXP platform) to secrete targeted bioeffector molecules and is a source of acellular derivatives (TRT CELLULAR).
Key advantages of the TXP cell population are:
- TXP cells are immunosuppressive and non-alloreactive – characters that have been confirmed by leading international clinician scientists.
- They are constitutively and profoundly anti-inflammatory, a property that is maintained in both the eTXP and TRT CELLULAR platforms.
- TXP cells are secretorily active within minutes following thaw from cryogenic storage and active for months in vivo.
- TXP cells are more biologically (physiologically) potent e.g. higher expression of wound healing genes than MSCs sourced from adult tissues (marrow or fat).
- They have shown proven efficacy in wound healing of several tissues: bone, cartilage and skin.
One example of TXP wound healing is that of skin which has been shown by both TRT and others. In the latter paper, both HUCPVC and conditioned medium were shown to accelerate skin wound healing. This can also be modeled in vitro by using a standard scratch wound healing assay as illustrated in the time-lapse video. In this case, the control cell population covers the scratch slowly, but with the addition of our HUCPVC derivative (HUE or “juice”), the wound healing is considerably accelerated.
The mechanism by which TXP cells heal wounds faster than other sources of mesenchymal cells can be explained, in part, by their gene expression. The volcano plot shows a comparison of TXP with bone marrow-derived “MSCs” and many of the most highly differentially expressed genes are associated with wound healing. But other comparisons are equally important, such as the increased anti-inflammatory capacity of TXP compared to bone marrow and fat-derived mesenchymal cells. The latter independent data shows a heat map of the constitutive anti-inflammatory phenotype of HUCPVCs compared to cells extracted from the stromal-vascular fraction of lipoaspirate tissue.